Takeda and TiGenix report new data highlighting maintenance of long-term remission of complex perianal Fistulas in Crohn’s disease patients with Cx601

by TIGENIX SAU

Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and Nasdaq: TIG) (“TiGenix”) today announced new data from the Phase 3 ADMIRE-CD clinical trial, ...

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

Iron deficiency is associated with large...

by Vall d’Hebron

The study shows that not only excess but also iron deficiency can have...

Photos Stream